DNA X, Inc. (SONM) DNA X, Inc., formerly known as Sonim Technologies, Inc. until its rebranding in January 2026, is a company established in 1999 and headquartered in San Diego, California. The firm specializes in delivering enterprise-grade 5G solutions across a broad international footprint, encompassing the United States, Canada, Europe, the Middle East, and the Asia-Pacific region. Their product portfolio includes a comprehensive range of ruggedized communication devices tailored for frontline and task workers. This lineup features models such as the Sonim XP10, Sonim XP5plus, Sonim XP3plus, Sonim XP Pro, as well as the XP100 4G and XP400 5G professional rugged phones, XP Pro 5G rugged smartphones, and XP3plus 5G rugged flip phones. Beyond handsets, DNA X, Inc. also provides connected solutions, offering both fixed wireless access and mobile hotspot devices. These include the Sonim H100 low- and mid-range mobile hotspots, the Sonim H700, and the advanced Sonim H500-series of 5G mobile hotspots. Complementing its hardware offerings, the company supplies proprietary SonimWare software and a selection of industrial-grade accessories. DNA X, Inc. distributes its products through a diverse network that includes wireless carriers, data device distributors, communications system integrators, and electronics resellers. The company's clientele spans various critical industries, including transportation and logistics, construction, manufacturing, facilities management, energy and utilities, mining, federal government agencies, and public safety organizations.
Sector: Telephone & Telegraph Apparatus
Industry: Communication Equipment
DNA X, Inc. NASDAQ:SONM Technology · Communication Equipment
All Press Release SEC Filings News
News
Critical Comparison: Sonim Technologies (NASDAQ:SONM) & Futu (NASDAQ:FUTU)
defenseworld.net • 21d ago News
Critical Analysis: Charles Schwab (NYSE:SCHW) & Sonim Technologies (NASDAQ:SONM)
defenseworld.net • 1mo ago SEC Filing ⚠ 3
SONM: 8-K · delisting
DNA X, Inc. (Nasdaq: SONM) received a letter from the Nasdaq Hearings Panel on August 28, 2026, determining that the company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies on the Nasdaq Capital Market to maintain stockholders' equity of at least $2.5 million.
Under the Panel's July 24, 2026 decision, SONM's securities remain subject to delisting if the company fails to maintain compliance with all Nasdaq Listing Rules through November 18, 2026.
The company is also subject to a mandatory panel monitor until August 28, 2027. If Nasdaq staff find the company out of compliance with the equity requirement again during that period, no compliance plan or cure period will be permitted and a delisting determination letter will be issued.
The regained compliance lifts the immediate delisting overhang, but the strict no-cure monitoring terms leave the company little margin for error on its balance sheet through mid-2027.
SEC 8-K • 1mo ago SEC Filing ⚠ 2
SONM: 8-K · leadership change
DNA X, Inc. (Nasdaq: SONM) filed an 8-K under Item 5.02 disclosing that on August 21, 2026 its compensation committee approved substitute cash grants for all board members, including CEO Mike Mulica, in lieu of RSU awards under the 2019 Equity Incentive Plan because no shares of common stock remain available under the plan.
Each Substitute Cash Grant is sized as phantom RSUs valued at $60,000 based on the stock's fair market value on August 21, 2026, and vests at the earlier of the company's 2027 annual meeting of stockholders or a change in control, with cash payable equal to the value of the underlying stock at that time.
The filing signals the company's equity incentive pool is fully depleted; replenishing it would require a shareholder-approved plan amendment, a potential future dilution point worth monitoring for this micro-cap.
SEC 8-K • 1mo ago AI analysis › SEC Filing ● Major ⚠ 8
SONM: 10-Q · periodic report
DNA X, Inc. (formerly Sonim Technologies, ticker SONM) reported a Q2 2026 net loss of $1.25 million on zero continuing-operations revenue. Its six-month net income of $5.09 million came entirely from a one-time $15.3 million pre-tax gain on selling the legacy phone and hotspot business to Pace Car Acquisition LLC for a $15 million purchase price in January 2026.
The company is now a pure-play crypto and AI trading platform after gaining full control of DNA X LLC from related party DNA Holdings on May 26, 2026, when DNA Holdings' put option terminated. The platform was closed to the public in March 2026 for development, averaged only $47 per month in commissions before closure, and is slated for relaunch in Q4 2026.
Liquidity hinges on related-party support: DNA Holdings, roughly 50% owned by director Scott Walker and holding about 15% of SONM shares, committed $8.1 million of Series B Convertible Preferred — $5.0 million in cash plus cancellation of a $3.1 million note. That leaves the company with no borrowed-money debt, and management asserts the $5 million funds operations for at least twelve months after the filing.
Red flags persist despite the recapitalization: the filing carries going-concern liquidity language, an unresolved material weakness in internal controls, a $1.23 million stockholders' deficit, and only $0.9 million of quarter-end cash. A proposed consulting agreement would issue 2,494,000 shares to DNA Holdings, Scott Walker and Brock Pierce, more than the 1,488,268 shares currently outstanding.
SEC 10-Q • 2mo ago AI analysis › Press Release ⚠ 3
DNA X, Inc. Reports Second Quarter 2026 Financial Results
DNA X reported second quarter financial results with zero revenue, as its AI trading platform remained closed to the public during the period, though management anticipates revenue generation to begin by late Q3 or early Q4.
The company significantly strengthened its balance sheet by raising $1.8 million via a convertible note during the quarter and an additional $5.0 million through preferred stock offerings after the quarter ended, ending the period with $0.9 million in cash.
Operating expenses for the quarter were $1.3 million, reflecting a downsizing following the sale of the company's legacy business.
• 2mo ago AI analysis › News
Patria Investments (NYSE:PAX) vs. Sonim Technologies (NASDAQ:SONM) Head to Head Analysis
defenseworld.net • 2mo ago SEC Filing ⚠ 4
SONM: NT 10-Q · late filing
DNA X, Inc. (formerly Sonim Technologies, ticker SONM) filed an NT 10-Q on August 14, 2026 notifying the SEC it cannot timely file its Form 10-Q for the quarter ended June 30, 2026. The delay resulted primarily from accounting for the sale of convertible debt and from complexities in accounting for variable interest entities under ASC Topic 810.
The accounting tangle traces to the termination of a put option held by DNA Holdings Venture, Inc., effected via Amendment No. 1 to a Membership Interest Purchase Agreement disclosed in an 8-K filed May 27, 2026. Following that Put Right Termination, the company determined that DNA X, LLC is fully controlled and must be consolidated into its GAAP financial statements, extending the financial close process.
Preliminarily, the company expects to report a net loss from continuing operations of approximately $1.0 million for Q2 2026, an improvement from approximately $1.9 million in Q2 2025, driven by lower interest expense after repaying promissory notes and an income tax benefit. It expects to file the Form 10-Q within the five-calendar-day grace period allowed under Rule 12b-25.
SEC NT 10-Q • 2mo ago SEC Filing ⚠ 4
SONM: 8-K/A · offering registration
DNA X, Inc. (Nasdaq: SONM) filed this 8-K/A to disclose that on August 7, 2026 it sold and issued the remaining 416,667 shares of Series B Preferred Stock under its Purchase Agreement for cash proceeds of $2.5 million, completing the equity raise.
The company states the transaction lifts estimated pro forma stockholders' equity to approximately $5.84 million, above the $2.5 million minimum required for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b)(1). Equity had been negative at an estimated -$1.5 million at the end of Q2 2026, so the financing and note conversion swing the balance sheet decisively positive on a pro forma basis.
Compliance is not yet confirmed: Nasdaq's formal determination that the company has evidenced compliance with the Equity Rule is still pending, and the pro forma equity figure is a management estimate presented for illustrative purposes. This is Amendment No. 2 to the original Form 8-K filed July 2, 2026, and was signed by CFO Clayton Crolius.
SEC 8-K/A • 2mo ago SEC Filing ⚠ 3
SONM: 8-K/A · offering registration
DNA X, Inc. secured $2.5 million in cash proceeds and cancelled $3.1 million in debt through the sale of Series B Preferred Stock, significantly improving its balance sheet. The company issued 929,864 shares of preferred stock and expects to issue an additional 416,667 shares by August 14, 2026.
Management believes the transactions push pro forma stockholders' equity to approximately $3.8 million, exceeding Nasdaq's $2.5 million minimum requirement for continued listing. The company is now awaiting formal confirmation of compliance from the exchange.
SEC 8-K/A • 3mo ago SEC Filing
SONM: 8-K · material agreement
DNA X, Inc. (SONM) terminated its ChEF Purchase Agreement and associated Registration Rights Agreement with Chardan Capital Markets LLC, effective May 28, 2026.
The original agreement, signed in September 2025, allowed Chardan to purchase up to $500 million of the company’s common stock, but no shares were sold under the facility prior to termination.
The termination eliminates potential future dilution from the facility but results in no immediate cash proceeds or change in capital structure for the company.
SEC 8-K • 4mo ago SEC Filing ● Major ⚠ 5
SONM: 8-K · debt financing
DNA X, Inc. (SONM) received a delisting determination from Nasdaq on May 22, 2026, due to failure to maintain the required $2.5 million in stockholders' equity, having reported a deficit of $983,000 in its Q1 2026 results. Trading of the company's common stock is scheduled to be suspended on June 2, 2026, unless the company successfully appeals the decision before a Nasdaq Hearing Panel, a process the company intends to initiate to stay the suspension.
Concurrently, the company closed a securities purchase agreement with DNA Holdings Venture, Inc. on May 26, 2026, issuing a convertible promissory note with a principal amount of $3,052,787.68. The purchase price consisted of $1.8 million in cash and the surrender of a prior $1.2 million bridge note plus accrued interest, with the new note maturing on December 31, 2026, and accruing interest at 10% per annum.
The new note is convertible into common stock at an initial price of $6.00 per share, subject to stockholder approval and various adjustments, including a discount to 80% of the market price during an event of default. The company's obligations under the note are secured by a first-priority lien on the membership interests of its wholly-owned subsidiary, DNA X, LLC, highlighting the secured nature of this financing amidst financial distress.
SEC 8-K • 4mo ago AI analysis › Press Release ⚠ 6
DNA X, Inc. Reports First Quarter 2026 Financial Results
DNA X, Inc. reported Q1 2026 net income of $6.3 million, driven entirely by the sale of its legacy mobile device business to NEXA Mobility. Continuing operations generated zero revenue and a net loss of $3.9 million, reflecting the company's transition phase.
The company completed its rebranding from Sonim Technologies and confirmed a strategic pivot to an AI-driven cryptocurrency trading platform. Management stated that resources are being reallocated to this high-growth sector, with the enhanced platform expected to launch later this year.
Liquidity remains tight, with only $1.2 million in cash from continuing operations. To support the new business, the company entered into an agreement to raise $1.8 million in new debt, citing working capital needs for the AI and crypto trading operations.
• 5mo ago AI analysis › SEC Filing ● Major ⚠ 6
SONM: 10-Q · periodic report
DNA X, Inc. (formerly Sonim Technologies) reported a net income of $6.3 million for Q1 2026, driven entirely by a $15.6 million gain from the sale of its legacy phone and hotspot business to Pace Car Acquisition LLC. The company’s new core business, the DNA X crypto trading platform, generated zero revenue from continuing operations and posted an operating loss of $3.9 million for the quarter.
The filing includes a going concern warning, stating there is substantial doubt about the company’s ability to continue operations. Management disclosed that $1.8 million in cash proceeds from a new convertible note issued to DNA Holdings on May 20, 2026, is expected to fund operations only through the note’s maturity in December 2026. If the note is not converted to equity, the company will need to raise additional capital to repay the $3.05 million principal.
Additionally, the company identified a material weakness in internal controls over financial reporting due to a lack of personnel with sufficient technical accounting expertise. This deficiency led to errors in recording complex transactions, including the acquisition of the crypto platform and the asset sale, requiring adjustments during the close process.
SEC 10-Q • 5mo ago AI analysis › SEC Filing ⚠ 4
SONM: NT 10-Q · late filing
DNA X, Inc. (formerly Sonim Technologies) filed a Form 12b-25 notification stating it cannot file its Q1 2026 10-Q on time. The delay is caused by the complex accounting required to present its legacy mobile phone and hotspot business as a discontinued operation following its disposition in the first quarter of 2026.
The company expects to report a net loss from continuing operations of approximately $3.6 million for the quarter ended March 31, 2026, a significant deterioration from the $0.7 million net loss reported in the same period last year. This increase in losses is attributed to severance and bonus payments triggered by the sale of the legacy business, as well as higher professional fees associated with the transaction's complexity.
The company anticipates filing the delayed 10-Q within five calendar days of the original due date. While the delay is transaction-specific, the widening loss profile and inability to close books promptly raise concerns about operational execution and near-term financial health.
SEC NT 10-Q • 5mo ago Press Release ● Major
DNA X, Inc. Reports Full Year 2025 Financial Results
newsfilecorp.com • 6mo ago 
